Kobayashi Junji
Department of Lifestyle-related Disease, Kanazawa University Graduate School of Medical Science, Takara-machi, Japan.
J Atheroscler Thromb. 2004;11(1):1-5. doi: 10.5551/jat.11.1.
Lipoprotein lipase (LPL) is a lipolytic enzyme involved in catalyzing the hydrolysis of triglycerides (TG) in chylomicrons and very low-density lipoprotein (VLDL) particles. Over the last decade, the clinical significance of measuring LPL mass without heparin injection has been increasingly studied. In earlier studies, it was shown that this marker was utilized to classify type 1 hyperlipoproteinemia, which is an extremely rare metabolic disorder. Later, researchers paid more attention to the clinical significance of measuring this parameter in more common metabolic disorders. Studies have shown that pre-heparin plasma LPL mass has significant relationships with serum lipid and lipoproteins, visceral fat area, and even a marker for acute inflammation, although this might be a metabolic surrogate marker which does not appear to be involved in catalyzing the hydrolysis of TG in TG-rich lipoproteins. We suggest that pre-heparin LPL mass in plasma or sera provides us with useful and important information on the pathophysiology of metabolic disorders or acute inflammation despite its simplicity from a practical point of view.
脂蛋白脂肪酶（LPL）是一种脂解酶，参与催化乳糜微粒和极低密度脂蛋白（VLDL）颗粒中的甘油三酯（TG）水解。在过去十年中，对不注射肝素情况下测量LPL质量的临床意义的研究越来越多。在早期研究中，表明该标志物可用于对I型高脂蛋白血症进行分类，这是一种极其罕见的代谢紊乱。后来，研究人员更加关注在更常见的代谢紊乱中测量该参数的临床意义。研究表明，肝素前血浆LPL质量与血清脂质和脂蛋白、内脏脂肪面积，甚至与急性炎症标志物都有显著关系，尽管这可能是一种代谢替代标志物，似乎不参与催化富含TG的脂蛋白中的TG水解。我们认为，血浆或血清中的肝素前LPL质量，尽管从实际角度来看很简单，但能为我们提供有关代谢紊乱或急性炎症病理生理学的有用且重要的信息。
